• Julie A Bettinger, David W Scheifele, Scott A Halperin, Wendy Vaudry, Jamie Findlow, Ray Borrow, Duccio Medini, Raymond Tsang, and members of the Canadian Immunization Monitoring Program, Active (IMPACT).
• Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada. Electronic address: jbettinger@cfri.ca.
• Vaccine. 2013 Dec 17; 32 (1): 124-30.

BackgroundIn collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009.MethodsIMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA).ResultsIn total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively.Conclusions4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

26 keywords...

hide…